Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region |
| |
| Authors: | Young Chan Kim Cesar Lopez-Camacho Joanne E Nettleship Nahid Rahman Michelle L Hill Laura Silva-Reyes Georgina Ortiz-Martinez Gloria Figueroa-Aguilar María Antonieta Mar Héctor Vivanco-Cid Christine S Rollier Nicole Zitzmann Martha Eva Viveros-Sandoval Raymond J Owens Arturo Reyes-Sandoval |
| |
| Institution: | 1.The Jenner Institute, Nuffield Department of Medicine, The Henry Wellcome Building for Molecular Physiology,University of Oxford,Oxford,UK;2.Division of Structural Biology, Wellcome Centre for Human Genetics,University of Oxford,Oxford,UK;3.Rutherford Appleton Laboratory,OPPF-UK, Research Complex at Harwell,Oxford,UK;4.Oxford Vaccine Group, Department of Paediatrics,University of Oxford and the NIHR Oxford Biomedical Research Centre, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital,Oxford,UK;5.Laboratorio de Hemostasia y Biología Vascular. División de Estudios de Posgrado. Facultad de Ciencias Médicas y Biológicas “Dr. Ignacio Chávez”,Universidad Michoacana de San Nicolás de Hidalgo, UMSNH,Morelia,Mexico;6.UMSNH–Oxford University of Oxford Clinical Research Laboratory (UMOCRL), Faculty of Biological and Medical Sciences “Dr. Ignacio Chávez”,Universidad Michoacana de San Nicolás de Hidalgo,Morelia,Mexico;7.Oxford Glycobiology Institute, Department of Biochemistry,University of Oxford,Oxford,UK;8.Laboratorio Estatal de Salud Pública,Secretaría de Salud de Michoacán,Morelia,Mexico;9.Instituto de Investigaciones Médico-Biológicas,Universidad Veracruzana,Veracruz,Mexico;10.HGZMF No. 12 Lázaro Cárdenas Michoacán dirección av. Lázaro Cárdenas No. 154 Col. Centro Lázaro Cárdenas Michoacán,Veracruz,Mexico |
| |
| Abstract: | BackgroundZika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications.MethodsWe designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera.ResultsReplacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro.ConclusionsResults obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
